Introduction

Hospital-acquired infections (HAIs) are a significant cause of morbidity and mortality worldwide, primarily among immunocompromised and elderly people, especially if the causative organism has developed resistance to a number of antimicrobial agents. *Pseudomonas aeruginosa*, one of the main Gram-negative bacilli that cause nosocomial infections, is known for its ability to propagate on medical devices, hospital environment and even in disinfectants. Infections due to this virulent organism are difficult to control and treat because of intrinsic resistance to a variety of antimicrobial agents [1]. It can also become resistant to multiple classes of antimicrobial agents by acquiring further resistance mechanisms, even during anti-pseudomonal chemotherapy [2]. The trend in increased antimicrobial resistance among bacterial pathogens severely limits the choice of effective antimicrobial agents. Carabapenems, including imipenem and meropenem, are β-lactam antibiotics used extensively for the treatment of *P. aeruginosa* infections. However, carabapenem-resistant *P. aeruginosa* (CRPA) has become common worldwide [3,4]. Due to treatment failure, drug-resistant strains have been associated with higher mortality, as well as prolonged length of hospital stay and increased hospital costs compared with susceptible ones [5] [6]. The major risk factors for spread of multidrug-resistant organisms (MDROs) are poor adherence to infection control measures and overuse of certain antimicrobials [7].

The misuse and overuse of antibiotics is widespread not only in developing countries but also in the developed world. The emergence and spread of antimicrobial resistance is a complex problem that is driven by numerous interconnected factors such as under- or overuse of antimicrobials [8]. Some researches have demonstrated that prior antimicrobial drug exposure is a strong risk factor for colonization and infection due to a drug-resistant pathogen [9,10]. However, other studies demonstrated that emergence of MDROs in a population was dependent on not only the direct effect of individual antimicrobial exposure but also the indirect effect due to increased bacterial resistance in others [11]. This might be because that the higher colonization pressure by MDROs is, the more likely the transmission of MDROs to other patients occurs [12]. Thus, studies that only evaluate individual exposure to antimicrobial agents may under-
the total effect of antimicrobial use on the acquisition of resistant bacteria because they do not consider these indirect effects from the antimicrobial exposures in other patients [13]. Ecological studies that use aggregated population-level data may be more suitable for such investigations because they consider the exposure of an entire population [7]. This interaction between antibiotic usage and the development of bacterial resistance to them is of particular interest with regard to *P. aeruginosa*. However, previous studies on resistance profiles of *P. aeruginosa* and antibiotic usage have reported inconsistent results at different institutions [9,14,15]. Aggregate antibiotic usage at local levels should therefore be monitored so that the associations between antimicrobial usage and emerging antimicrobial resistance can be evaluated. The objectives of this study were to give an overview of trends in antibiotic usage and resistance of *P. aeruginosa* isolated from patients with HAIs in a tertiary care hospital in northeast China from 2003 through 2011.

**Materials and Methods**

**Ethics Statement**

This study was approved by the institutional ethics committee of the First Hospital of Jilin University. The committee waived the need for informed consents (both written and oral) from participants because this was a retrospective observational study, involved very minimal risk to the subjects, did not include intentional deception, and did not involve sensitive populations or topics; this waiver does not adversely affect the rights and welfare of the subjects.

**Hospital Setting and Definitions**

First Hospital is a teaching hospital affiliated with Jilin University in northeast China. It offers both primary and tertiary referral care. The number of beds progressively increased from 921 in 2003 to 2896 in 2011.

Center for Diseases Control (CDC) criteria were used for the diagnosis of nosocomial infections. HAI was defined as occurrence of infection after hospital admission, without evidence that the infection was present or incubating (≤ 48 h) on admission.

**Bacterial Isolates**

*P. aeruginosa* isolates were subcultured to blood agar and McConkey agar plates at this laboratory for purity check and to confirm species identification. Identification was performed using the VITEK 2 system (bioMérieux, Marcy l’Etoile, France) in microbiological laboratory of the hospital. Isolates of the same species from the same patient collected during the same in-patient stay were considered duplicate isolates, and only the first isolate was included from the analysis.

**Antimicrobial Susceptibility Testing**

*In vitro* susceptibilities of *P. aeruginosa* to 12 antimicrobial agents (Oxoid) were determined by the disk diffusion method and susceptibility profiles were determined using zone diameter interpretive criteria, as recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2011 (M100-S21). Breakpoints of cefoperazone/sulbactam were interpreted according to the manufacturer’s recommendations. Mueller-Hinton agar (Oxoid) was used for all susceptibility tests. The proportion of resistant isolates was calculated by dividing the number of resistant isolates of *P. aeruginosa* by the total number of the isolates tested against the corresponding antibiotic multiplied by 100. *Escherichia coli* ATCC 25922, *E. coli* ATCC 35218, *Klebsiella pneumoniae* ATCC 700603, and *P. aeruginosa* ATCC 27853 were used as quality control strains for each batch of tests. Imipenem-resistant or meropenem-resistant *P. aeruginosa* was considered as CRPA. For analysis of susceptibility rates in different year and patient groups, we used the WHONET software.

**Antimicrobial Utilization**

We retrospectively obtained the antimicrobial utilization information for all patients by using the hospital pharmacy computer database. The evaluated periods were from 2003 through 2011. Defined daily dose (DDD) was developed by the World Health Organization (WHO) Anatomical Therapeutical Chemical (ATC)/DDD index 2011 to standardize the comparative usage of various drugs between themselves or between different healthcare environments for all adult wards, and is defined as the assumed average maintenance dose per day for a drug used for its main indication. The amount of antimicrobials used was calculated as DDD per 1,000 patients-days as follows: total usage measured in DDDs/number of days in the period of data collection × number of patients) × 1,000 [8]. The six classes of antimicrobial agents analyzed in this study were: anti-pseudomonal penicillins (including piperacillin, and ticarcillin), β-lactam/β-lactamase inhibitors with anti-pseudomonal effects (cefoperazone/sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanate), anti-pseudomonal cephalosporins (ceftazidime, aztreonam, and cefepime), anti-pseudomonal carbapenems (imipenem/cilastatin, and meropenem), anti-pseudomonal fluoroquinolones (ciprofloxacin, and levofloxacin), and aminoglycosides (amikacin, tobramycin, and gentamicin), modified from suggestion by CLSI in 2011.

**Statistical Analysis**

Time series analysis model was used to analyze the trends in annual antimicrobial usage and antimicrobial resistance trends of *P. aeruginosa* within the study period. Autoregressive integrated moving average (ARIMA) models with cross-correlation consideration were used to determine the relationships between the trend in antimicrobial resistance of *P. aeruginosa* and antimicrobial usage over time by taking into account one time lag (delay for observing an effect of antimicrobial use) and the autocorrelation patterns. The β value indicates the variation of dependent variables when independent variables change one unit at uniform time intervals. All analyses were performed with the Statistical Package for the Social Sciences version 18.0 (SPSS, Chicago, IL, USA). All reported *P* values were two-sided, and values of *P*<0.05 were considered statistically significant.

**Results**

**Bacterial Isolates**

Two thousand four hundred and ten consecutive non-duplicate isolates of *P. aeruginosa* were isolated during the nine-year study period in the hospital. Among the isolates, episodes from patients with HAIs were 747. The mean age of patients with HAIs was 61.4 years. The strains were cultured from respiratory samples (201 isolates, 26.9%), followed by blood (179, 24.0%), secretions and pus (145, 19.4%), urine (102, 13.7%), pleural fluid and abdominal fluid (60, 9.1%), and bile (52, 7.0%). Three hundred and twenty-nine strains (44.0%) were from intensive care unit (ICU). Source breakdown of *P. aeruginosa* is listed in Table S1.

**Trends of *P. aeruginosa* Isolated from Patients with HAIs in Resistance to Different Antimicrobial Agents over Time**

Antimicrobial resistance trends of *P. aeruginosa* isolated from patients with HAIs during the nine-year study period are listed in
amikacin remained stable. During the same period, the resistance rates to gentamicin and increased 4.6% every year according to time series analysis. From 2003 through 2011, the rates of imipenem-resistant or meropenem-resistant P. aeruginosa (CRPA) isolated from patients with HAIs were 14.3%, 17.1%, 21.1%, 24.6%, 37.0%, 48.8%, 56.4%, 51.2%, and 54.1%.

### Discussion

The burden of HAIs due to MDROs may vary widely according to geographical region, healthcare setting, type of pathogen and antimicrobial substance. P. aeruginosa is an opportunistic pathogen responsible for a large spectrum of invasive antimicrobial agents remained stable over nine years. The association between resistance rates of P. aeruginosa isolated from patients with HAIs and usage of antimicrobial agents of different classes from 2003 through 2011 are shown in Table 3. ARIMA models demonstrated that anti-pseudomonal carbapenems usage was strongly correlated with the prevalence of imipenem and meropenem-resistant P. aeruginosa \( (P<0.001) \). Anti-pseudomonal cephalosporins were positive correlated with the prevalence of ceftazidime and cefepime-resistant P. aeruginosa \( (P=0.043) \), whereas the usage of anti-pseudomonal fluoroquinolones fluctuated only in recent three years (2008–2010). We found the annual usage of total antimicrobial agents remained stable over nine years.

Correlation between quarterly usage of antimicrobial agents and rates of CRPA isolated from patients with HAIs in the hospital from 2003 through 2011 are shown in Figure 1. ARIMA models demonstrated that increasing of quarterly CRPA was strongly correlated at one time lag with quarterly use of anti-pseudomonal carbapenems \( (\beta=1.097, P<0.001) \); however, increasing in quarterly CRPA was associated with none of the other classes of antimicrobial agents.

**Table 1. Time series analysis demonstrated a significant increase in the resistance rates of P. aeruginosa to ticarcillin/clavulanic acid, piperacillin/tazobactam, cefoperazone/sulbactam, piperacillin, imipenem, meropenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin during nine years in the hospital \( (P<0.001) \).

The increase of resistance rate of P. aeruginosa to meropenem was the highest during the nine-year study period. The \( \beta \) value indicated that resistance rate of P. aeruginosa to meropenem increased 4.6% every year according to time series analysis. During the same period, the resistance rates to gentamicin and amikacin remained stable.

The rates of imipenem-resistant or meropenem-resistant P. aeruginosa (CRPA) isolated from patients with HAIs were 14.3%, 17.1%, 21.1%, 24.6%, 37.0%, 48.8%, 56.4%, 51.2%, and 54.1% from 2003 through 2011.

### Association of Hospital Antimicrobial Usage and Resistance of P. aeruginosa

Annual usage trends of antimicrobial agents used for the treatment of infections during the nine-year study period are listed in Table 2. There were no data about the usage of anti-pseudomonal penicillins because piperacillin and ticarcillin were not be used in the hospital. A significant increase in usage was seen for anti-pseudomonal carbapenems over nine years \( (P<0.001) \). Use of anti-pseudomonal aminoglycosides, cephalosporins, and \( \beta \)-lactam/\( \beta \)-lactamase inhibitors with anti-pseudomonal effect remained stable over the nine-year period. Time series analysis demonstrated the annual use of anti-pseudomonal fluoroquinolones slightly decreased \( (P=0.043) \), whereas the usage of anti-pseudomonal fluoroquinolones fluctuated only in recent three years (2008–2010). We found the annual usage of total antimicrobial agents remained stable over nine years.

The association between resistance rates of P. aeruginosa isolated from patients with HAIs and usage of antimicrobial agents of different classes from 2003 through 2011 are shown in Table 3. ARIMA models demonstrated that anti-pseudomonal carbapenems usage was strongly correlated with the prevalence of imipenem and meropenem-resistant P. aeruginosa \( (P<0.001) \). Anti-pseudomonal cephalosporins were positive correlated with the prevalence of ceftazidime and cefepime-resistant P. aeruginosa \( (P=0.043) \), whereas the usage of anti-pseudomonal fluoroquinolones fluctuated only in recent three years (2008–2010). We found the annual usage of total antimicrobial agents remained stable over nine years.
diseases in healthcare settings, including pneumonia, urinary tract infections and bacteremia [16]. In humans, *P. aeruginosa* has been isolated from all cultivable sites. The most common specimen types from patients with HAIs in the present study were respiratory samples, blood, secretions and pus over the years in this hospital.

**Resistance of *P. aeruginosa* Isolated from Patients with HAIs over Time**

One aim of this study was to evaluate the resistance trend of *P. aeruginosa* isolated from patients with HAIs in recent years in this hospital. The present study showed a significant increase in resistance rates of *P. aeruginosa* to ticarcillin/clavulanic acid, piperacillin/tazobactam, ceferazone/sulbactam, piperacillin, imipenem, meropenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin over time in the hospital. The resistance rate of *P. aeruginosa* to these antibiotics increased from 2.0% to 4.6% every year according to time series analysis. The increase of resistance rate of *P. aeruginosa* to meropenem was the highest during the nine-year study period. The resistance rates of ticarcillin/clavulanic acid and gentamicin were higher than 60.0% in almost years.

**Table 2. Annual usage trends of antimicrobial agents used for the treatment of infections in First Hospital of Jilin University, 2003–2011.**

| Antimicrobial agents | Antimicrobial usage (DDDs/1000 patients/day) by year | Time-series analysis model |
|---------------------|---------------------------------------------------|--------------------------|
|                     | 2003  | 2004  | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | β     | P     | Trend     |
| β-lactam/β-lactamase inhibitors | 75.2  | 156.5 | 282.4 | 163.5 | 102.3 | 56.7  | 78.3  | 54.4  | 73.7  | −11.314 | 0.263 | Stable     |
| Cephalosporins      | 122.2 | 105.3 | 48.6  | 108.6 | 161.7 | 137.9 | 193.9 | 141.9 | 131.2 | 7.591   | 0.098 | Stable     |
| Carbapenems         | 3.2   | 5.1   | 7.7   | 9.1   | 12.1  | 14.3  | 25.2  | 28.2  | 29.8  | 3.526   | <0.001| Increasing |
| Aminoglycosides     | 43.9  | 44.4  | 44.7  | 42.8  | 40.7  | 32.7  | 37.3  | 75.4  | 24.3  | 0.487   | 0.647 | Stable     |
| Fluoroquinolones    | 24.5  | 21.5  | 22.1  | 23.1  | 23.8  | 12.9  | 13.9  | 11.6  | 23.5  | −1.090  | 0.043 | Decreasing |
| Total antimicrobial agents | 269.0 | 332.8 | 405.5 | 347.1 | 340.6 | 254.5 | 348.6 | 311.5 | 282.5 | −3.950  | 0.463 | Stable     |

**Table 3. Correlation between resistance rates of *P. aeruginosa* isolated from patients with HAIs and usage of antimicrobial agents in First Hospital of Jilin University, 2003–2011.**

| Antimicrobial agents       | Time-series analysis model |
|---------------------------|---------------------------|
|                           | β   | P    | Correlation |
| Ticarcillin/Clavulanic acid | −0.033 | 0.149 | Negative     |
| Piperacillin/Tazobactam    | −0.066 | 0.209 | Negative     |
| Ceferazone/Sulbactam       | −0.048 | 0.331 | Negative     |
| Imipenem                   | 1.238 | <0.001| Positive     |
| Meropenem                  | 1.241 | <0.001| Positive     |
| Ceftazidime                | 0.186 | 0.010 | Positive     |
| Cefepime                   | 0.195 | 0.007 | Positive     |
| Gentamicin                 | 0.053 | 0.626 | Negative     |
| Amikacin                   | 0.002 | 0.976 | Negative     |
| Ciprofloxacin              | −0.477 | 0.252 | Negative     |
| Levofloxacin               | −0.800 | 0.163 | Negative     |

doi:10.1371/journal.pone.0078604.t003

during the same period, the resistance rates to gentamicin and amikacin remained stable. *P. aeruginosa* possesses a considerable degree of natural resistance to many antibiotics. This intrinsic resistance is due to low permeability of its outer membrane, antibiotics such as aminoglycosides, cephalosporins, fluoroquinolones and penicillins are recently non-sensitive to *P. aeruginosa* [17]. The growing threat of antimicrobial resistance in *P. aeruginosa* results from the extraordinary capacity of this microorganism for developing resistance to almost any available antibiotic by the selection of mutations in chromosomal genes and from the increasing prevalence of transferrable resistance determinants, particularly those encoding class B carbapenemases (or metallo-β-lactamases [MBLs]) or extended-spectrum β-lactamases (ESBLs), frequently cotransferred with genes encoding aminoglycoside-modifying enzymes [18,19]. Among the mutation-mediated resistance mechanisms, particularly noteworthy are those leading to the repression or inactivation of the carbapenem porin OprD, the hyperproduction of the chromosomal cephalosporinase AmpC, or the upregulation of one of the several efflux pumps encoded in the *P. aeruginosa* genome [20,21]. Furthermore, the accumulation of many of these chromosomal mutations can lead to the emergence of MDR strains, which eventually may be responsible for notable outbreaks in the hospital setting [22].

The control of MDR *P. aeruginosa* infections is a public health priority worldwide [23]. This study of 747 *P. aeruginosa* isolated from patients with HAIs over the years revealed the continuous increase of antimicrobial resistance. Carbapenems such as imipenem and meropenem are the last resort of drugs for the treatment of MDR pathogens including *P. aeruginosa*. However, the incidence of carbapenem resistance in *P. aeruginosa* increased steadily in the 2000s [3,4]. Resistance to carbapenems, which is often accompanied with resistance to multiple other agents, has increased in all parts of the world [24]. Our study revealed the rapid increase in the prevalence of CRPA isolated from patients with HAIs over the years the hospital, from 14.3% in 2003 to 54.1% in 2011. The results of the present study indicate a strong burden of CRPA in the hospital. The development, spread, and persistence of these resistance mechanisms complicates the selection of antimicrobial therapy when trying to avoid the increased selective pressures caused by the utilization of any one class of antimicrobial agents.

**Association of Hospital Antimicrobial Usage and Resistance of *P. aeruginosa***

Another endpoint of this ecological study was to evaluate the association between resistance of *Pseudomonas aeruginosa* isolated
from patients with HAIs and hospital antimicrobial usage in this hospital. Use of anti-pseudomonal aminoglycosides, cephalosporins, and β-lactam/β-lactamase inhibitors with anti-pseudomonal effect remained stable over time. The use of β-lactam/β-lactamase inhibitors with anti-pseudomonal effect increased significantly from 2003 to 2005 in that the increase of ESBL resistance in Enterobacteriaceae has necessitated the use of β-lactam/β-lactamase inhibitors with anti-pseudomonal effect during this period in the hospital. The usage of anti-pseudomonal aminoglycosides increased significantly in 2010, maybe due to changes of antimicrobial policies in the hospital. A significant increase in usage was seen for anti-pseudomonal carbapenems over nine years in present study. Anti-pseudomonal carbapenems usage was strongly correlated with the prevalence of imipenem and meropenem-resistant P. aeruginosa isolated from patients with HAIs. Increasing of quarterly CRPA was strongly correlated at one time lag with quarterly use of anti-pseudomonal carbapenems. Previous studies used individual-level data to investigate the association between antibiotic exposure and acquisition of resistant P. aeruginosa, and few studies have investigated aggregated population-level data [25–27]. Studies using individual-level data would neglect the indirect, and possibly significant, effects of antibiotics exposure of people who are near the index person [7]. Our present study used hospital-wide population-level data of 747 patients. The current study is an ecological study to investigate the association between antibiotic exposure and acquisition of resistant P. aeruginosa.

In vitro and in vivo studies have already documented that exposure to carbapenems increases the risk for acquiring CRPA [28,29]. For Enterobacteriaceae, β-lactamases such as ESBLs and plasmid and chromosomal AmpCs are the most important resistance mechanisms. Since the ESBL SHV-2 was first reported in China in the 1990s, ESBL-producing Enterobacteriaceae have spread rapidly, particularly after 2000. The prevalence of ESBL-producing E. coli strains varies across different regions of China, with the lowest incidence in Urumqi (28.5%, Northwest), and the highest in Wuhan (78%, Central-South) in 2008 [30]. The increased importance of ESBL resistance in Enterobacteriaceae has necessitated the use of ESBL stable β-lactams like carbapenems in China. This followed an outbreak of CRPA infections due to use of carbapenems increased substantially in China. We found that prior exposure of imipenem and meropenem was associated with CRPA acquisition in this study. Imipenem and meropenem are broad-spectrum antibiotics with activities against most Gram-negative bacteria, including many nonfermentative Gram-negative bacilli. Therefore, it is understandable that carbapenems usage could change the bacterial flora in patients and facilitate the colonization and/or infection of resistant bacteria, such as CRPA.

We found no correlation between the usage of anti-pseudomonal β-lactam/β-lactamase inhibitors, aminoglycosides, and fluoroquinolones and the prevalence of resistant P. aeruginosa. There are several possible explanations for the lack of significant correlation between hospital antimicrobial usage and resistance in our study. As had previously been pointed out, resistance selection pressure occurs at the individual level and calculating antibiotic prescription using DDD measurements does not measure individual exposure to antibiotics [28,29]. A minority of patients is exposed to the majority of broadspectrum antibiotic prescriptions in the hospital, and these are mainly the patients who are susceptible to infections by antibiotic-resistant pathogens. Hence, although DDD measurements are useful for comparison and benchmarking, they may not correlate well with subsequent antibiotic resistance development due to the inherent biases. In our study, although hospital antimicrobial usage had fluctuated, the prescription volumes had generally remained high. It is possible that beyond a certain critical threshold of antibiotic use, antibiotic resistance becomes decoupled from prescription. However, such a threshold—if it exists—has not been defined.
In conclusion, antimicrobial resistance of *P. aeruginosa* and antimicrobials usage is significant increasing in the hospital. Our data demonstrated positive correlation between anti-pseudomonal antimicrobial usage and *P. aeruginosa* resistance to several classes of antibiotics, but not all antimicrobial agents in the hospital. The effective treatment of infections caused by *P. aeruginosa* includes prevention when possible, source control measures as necessary and prompt administration of appropriate antibacterial agents. Antibacterial de-escalation should be pursued in patients with an appropriate clinical response, especially when antibacterial susceptibilities are known. Hand hygiene and barrier nursing are important to keep the spread of infection in check. Surveillance is therefore important in providing useful information for physicians in choosing empirical antibiotics. It also helps to address specific resistant issues within a region to help identify targeted intervention measures.

**Supporting Information**

**Table S1** Source breakdown of *P. aeruginosa* isolated from HAIs patients in First Hospital of Jilin University, 2003–2011. Patient locations are defined as ICU and non-ICU. Specimen types are expressed as respiratory, secretions and pus, urine, blood, pleural fluid and abdominal fluid and bile.

**Acknowledgments**

We are grateful to Jing Jiang, Zhifang Jia, and Suyan Tian who have assisted us to make statistical analysis.

**Author Contributions**

Conceived and designed the experiments: JX HW QZ. Performed the experiments: JX XD HW. Analyzed the data: JX XD HW QZ. Contributed reagents/materials/analysis tools: JX XD HW QZ. Wrote the paper: JX HW QZ.

**References**

1. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999) Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antimicrobial agents. Antimicrob Agents Chemother 43: 1579–1582.

2. Rossolini GM, Mantegnoli E (2005) Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 11 Suppl 4: 17–22.

3. Cavalcanti FL, Almeida AC, Vilela MA, Morais MM, Morais Junior MA (2012) Changing the epidemiology of carbapenem-resistant Pseudomonas aeruginosa in a Brazilian teaching hospital: the replacement of Sao Paulo metallo-beta-lactamase-producing isolates. Mem Inst Oswaldo Cruz 107: 420–423.

4. Nagao M, Inuma Y, Igawa J, Saijo T, Yamashita K, et al. (2011) Control of an outbreak of carbapenem-resistant Pseudomonas aeruginosa in a haematology-oncology unit. J Hosp Infect 79: 49–53.

5. Cattaneo C, Antoniazzi F, Casari S, Ravicella G, Gelmii M, et al. (2012) *P. aeruginosa* bloodstream infections among hematological patients: an old or new question? Ana Hematol 91: 1299–1304.

6. Morata L, Cobo-Trigueros N, Martínez JA, Soriano A, Almeida M, et al. (2012) Inheritance of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 56: 4833–4837.

7. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, et al. (2012) Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 7: e37788.

8. Arda B, Sipahi OR, Yamazhan T, Tasbakan M, Pulhuka H, et al. (2007) Short-term effect of antibiotic control policy on the usage patterns and cost of antimicrobials, mortality, nosocomial infection rates and antibacterial resistance. J Infect 55: 41–48.

9. Tacconelli E, De Angelis G, Cataldo MA, Mantegnoli E, Spanu T, et al. (2009) Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 53: 4264–4269.

10. Tacconelli E, Venkataraman I, De Girolami PC, EM DA (2004) Methylillin-resistant Staphylococcus aureus bacteremia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 53: 474–479.

11. Manikal VM, Landman D, Saurina G, Oyeha E, Lal H, et al. (2000) Epidemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 31: 101–106.

12. Williams VR, Callery S, Vearncombe M, Simor AE (2009) The role of colonization pressure in nosocomial transmission of methicillin-resistant Staphylococcus aureus. Am J Infect Control 37: 106–110.

13. Lipschitz M, Samore MH (2002) Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 8: 347–354.

14. Hsu LY, Tan T, Tan VH, Kwa A, Fisher DA, et al. (2010) Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 54: 1173–1178.

15. Slam D, Sarwari AR, Petros KO, Mcniight RL, Sager RB, et al. (2011) Impact of a Multimodal Antimicrobial Stewardship Program on Pseudomonas aeruginosa Susceptibility and Antimicrobial Use in the Inpatient Care Unit Setting. Crit Care Res Pract 2011: 416426.

16. Shamba J, Pazhanimurugan R, Gopikrishnan V, Balagurunathan R (2013) Mechanism of drug resistance, characterization of plasmid-borne determinants and transformation study in *P. aeruginosa* from burn and ICU units-its susceptibility pattern. Burns 39: 643–5.

17. Laner PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22: 582–610.

18. Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa*: our worst nightmare? Clin Infect Dis 34: 634–640.

19. Goldstein EJ, Citron DM, Peraino V, Elpont V, Melbom AR, et al. (2009) Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 53: 5123–5126.

20. Cabot G, Orampa-Sosa AA, Tahau F, Macia MD, Rodriguez C, et al. (2011) Overexpression of AmpC and efflux pumps in *Pseudomonas aeruginosa* isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55: 1906–1911.

21. Deplano A, Denis O, Poirel L, Hocquet D, Nooshoff C, et al. (2005) Molecular characterization of an epidemic clone of panantibiotic-resistant *Pseudomonas aeruginosa*. J Clin Microbiol 43: 1198–1204.
23. Lipovy B, Rihova H, Hanulianova M, Gregorova N, Suchanek I, et al. (2010) Prevalence and resistance of Pseudomonas aeruginosa in severely burned patients: a 10-year retrospective study. Acta Chir Plast 52: 39–43.

24. Shigemi A, Matsumoto K, Yaji K, Shimoizono Y, Takeda Y, et al. (2009) Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 34: 589–591.

25. Martinez JA, Delgado E, Marti S, Marco F, Vila J, et al. (2009) Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med 35: 439–447.

26. Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM (2005) Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 49: 3663–3667.

27. Ozkurt Z, Ertik M, Erol S, Altoparlak U, Akcay MN (2005) The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 31: 870–873.

28. Baumgart AM, Molinari MA, (2010) Silveira AC. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14: 433–436.

29. Scheffer MC, Gales AC, Barth AL, Carmo Filho JR, Dalla-Costa LM (2010) Carbapenem-resistant Pseudomonas aeruginosa: clonal spread in southern Brazil and in the state of Goias. Braz J Infect Dis 14: 508–509.

30. Xiao YH, Giske CG, Wei ZQ, Shen P, Hedlin A, et al. (2011) Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat 14: 236–250.